Stay updated with breaking news from Solid Biosciences Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Solid Biosciences (NASDAQ:SLDB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage presently has a $1.25 target price on the stock. Zacks Investment Research‘s target price suggests a potential downside of 11.97% from the company’s current […]
Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) insider Carl Ashley Morris sold 22,665 shares of Solid Biosciences stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $1.10, for a total transaction of $24,931.50. The transaction was disclosed in a legal filing with the SEC, which […]
Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for shares of Solid Biosciences in a research note issued on Tuesday, March 15th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.17) per share for the […]
Solid Biosciences (NASDAQ:SLDB – Get Rating) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03, Fidelity Earnings reports. Shares of SLDB stock opened at $1.00 on Tuesday. The company has a market cap of $109.78 million, a PE ratio of […]
<p><span>Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on </span><span class="xn-chron">Monday, December 20, 2021</span><span>.</span></p>